The high cost of care, this is where it begins.
Some potentially great news for patients with hypertension some time down the road as long as the clinical trials go off without a hitch. Investors seem to be pleased with the preliminary results and so does the stock market. However this is what healthcare has become, this is the beginning of one of the many ailments with our current healthcare delivery system - Investor interests.
From an ethical point of view it seems to be bad form to make a living off others ill fate, but that is what healthcare does. We (healthcare at large) disguise this ugly truth by promoting the benefits of our abilities to care for the individual, and the high quality care and compassion that exist in our organizations – please forgive the cynicism.
While PS433540 as it is now called may actually be of great use and benefit in the management of hypertension I wonder what the cost will be for patients. Will the price tag cause a rise in the diastolic of prospective patients so that investors can smile at a great ROI, or will the charge for the new drug once it hits pharmacies be reasonable. This is where the cost of healthcare comes from; this is where the target of controlling healthcare costs should be, not by reducing reimbursement rates by payers.
About the Author
Mike Pringle is the author of Healthcare Today where he offers commentary and insight regarding today’s healthcare issues. Additionally he provides regular commentary for Red Scrubs and editorial content for Future Healthcare. He has over 20 years of nursing experience working both domestically and internationally. Mike has a Bachelor’s Degree in Nursing and a Masters Degree in Public Administration with a Healthcare emphasis. He specializes in both Emergency and Critical Care Nursing. He currently works at Falmouth Hospital as a Shift Manager for the emergency department.
